Illustration of amyloid plaques (orange) between brain cells
Science Photo Library/Alamy
In early July, the U.S. Food and Drug Administration (FDA) approved a treatment called donanemab for people with early-stage Alzheimer's disease, the second drug shown to slow the progression of the disease and the third FDA-approved drug to remove amyloid proteins that build up in the brains of people with Alzheimer's.
The FDA's approval of three new drugs in just over three years (donanemab, lecanemab, and aducanumab) has led some to proclaim a breakthrough in the treatment of Alzheimer's disease. Japan, South Korea, China, and…
Source: www.newscientist.com
